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ABSTRACT
Background The Community- Level Interventions for 
Pre- eclampsia (CLIP) trials (NCT01911494) in India, 
Pakistan and Mozambique (February 2014–2017) involved 
community engagement and task sharing with community 
health workers for triage and initial treatment of pregnancy 
hypertension. Maternal and perinatal mortality was less 
frequent among women who received ≥8 CLIP contacts. 
The aim of this analysis was to assess the incremental 
costs and cost- effectiveness of the CLIP intervention 
overall in comparison to standard of care, and by PIERS 
(Pre- eclampsia Integrated Estimate of RiSk) On the Move 
(POM) mobile health application visit frequency.
Methods Included were all women enrolled in the three 
CLIP trials who had delivered with known outcomes by 
trial end. According to the number of POM- guided home 
contacts received (0, 1–3, 4–7, ≥8), costs were collected 
from annual budgets and spending receipts, with inclusion 
of family opportunity costs in Pakistan. A decision tree 
model was built to determine the cost- effectiveness of the 
intervention (vs usual care), based on the primary clinical 
endpoint of years of life lost (YLL) for mothers and infants. 
A probabilistic sensitivity analysis was used to assess 
uncertainty in the cost and clinical outcomes.
Results The incremental per pregnancy cost of the 
intervention was US$12.66 (India), US$11.51 (Pakistan) 
and US$13.26 (Mozambique). As implemented, the 
intervention was not cost- effective due largely to minimal 
differences in YLL between arms. However, among women 
who received ≥8 CLIP contacts (four in Pakistan), the 
probability of health system and family (Pakistan) cost- 
effectiveness was ≥80% (all countries).
Conclusion The intervention was likely to be cost- 
effective for women receiving ≥8 contacts in Mozambique 
and India, and ≥4 in Pakistan, supporting WHO guidance on 
antenatal contact frequency.
Trial registration number NCT01911494.
INTRODUCTION
The hypertensive disorders of pregnancy are 
one of the primary global causes of maternal 
and fetal mortality1 and morbidity, with pre- 
eclampsia specifically resulting in an esti-
mated 76 000 maternal and 500 000 peri-
natal deaths annually.2 Recently, using data 
from the Community- Level Interventions for 
Pre- eclampsia (CLIP) cluster randomised 
controlled trials (cRCTs) in India, Pakistan, 
Mozambique and Nigeria, we estimated the 
incidence of pregnancy hypertension in low 
and middle- income countries (LMIC) to be at 
least 10%, at least as high as in well- resourced 
settings.3
Many of the pregnancy hypertension- related 
deaths occur either prior to women arriving 
at a health facility or after arriving there too 
late to prevent a fatal complication.4 As a 
result, there has been interest in mobilising 
front- line providers, such community health-
care workers (CHWs) to provide earlier care 
and facilitate referral to facility.5 6 However, 
it has not been demonstrated that such an 
approach was effective or cost- effective.
The CLIP cRCTs in India, Pakistan and 
Mozambique leveraged the existing CHW 
workforce to identify, implement initial 
treatment and triage hypertensive pregnant 
women in their communities to facility, as well 
as to provide education to communities about 
obstetric emergencies and the hypertensive 
disorders of pregnancy specifically. There 
was no evidence that the CLIP interven-
tion was effective in decreasing a composite 
of maternal and perinatal mortality and 
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morbidity as implemented by the existing workforce. 
Consequently, the intervention was received by fewer 
women than anticipated (ie, 7055 (90.0%) in India, 11 
399 (56.3%) in Pakistan and 4809 (60.4%) in Mozam-
bique).7–10 An a priori- determined contact frequency 
analysis indicated effectiveness in reducing maternal and 
perinatal mortality and morbidity among women who 
received the intervention per protocol; at least four visits 
in Pakistan, and at least eight visits in both India and 
Mozambique.7–10 These findings were consistent with the 
recent WHO eight antenatal care contacts model.
Health economic analyses in such global health trials 
are required, as they often provide policy direction for 
resource allocation for improving maternal and newborn 
health.11 Assessing cost- effectiveness of CHW- led inter-
ventions has been a matter of debate,12 and definitive 
determination of whether or not such an approach is a 
fiscally viable way of reducing adverse maternal and fetal 
outcomes is required.
The aim of this study was to assess the cost- effectiveness 
of the CLIP trial intervention in each of India, Pakistan 
and Mozambique in comparison to standard of care, and 
to determine whether or not cost- effectiveness differed 
between countries or according to the number of CHW- 
provided contacts a woman received.
METHODS
This was a planned secondary analysis of the clinical and 
cost data collected from the CLIP cRCTs in Karnataka 
state, India, Sindh province in Pakistan, and Maputo and 
Gaza provinces in Mozambique,13 based on a previously 
published protocol14 and reported in line with a Consoli-
dated Health Economic Evaluation Reporting Standards 
checklist.15 (See online supplemental appendix 1 for the 
Statistical Analysis Plan.)
Study population
The CLIP trials targeted pregnant women (15–49 years 
in India and Pakistan, and 12–49 years in Mozambique) 
across all intervention and control clusters (12 in each of 
India and Mozambique, and 20 in Pakistan). All women 
enrolled provided written consent. All were included in 
the economic analysis provided they had delivered by trial 
end and had data on the primary outcome of a composite 
of maternal and perinatal morbidity or mortality.
CLIP intervention
The methods for the CLIP trials are described in detail 
elsewhere.8 13 Briefly, each of the cRCTs aimed to reduce 
all- cause maternal and perinatal morbidity and mortality 
by community- level initial triage and treatment of hyper-
tensive women in their community, and timely transfer 
to facility. The intervention combined community 
engagement and pregnancy hypertension- focused home 
contacts by CHWs (ie, accredited social health activists 
and auxiliary nurse midwives (India), female health 
workers (Pakistan) and Agentes Polivalentes Elemen-
tares (Mozambique)). Community engagement meet-
ings focused on pre- eclampsia awareness and education 
around birth preparedness and complication readiness, 
and included the pregnant women themselves, as well 
as their family members and community stakeholders. 
CHW- led home contacts were centred around the use of 
the PIERS (Pre- eclampsia Integrated Estimate of RiSk) 
On the Move (POM) mobile health application for risk 
stratification.16 The POM application helped CHWs to 
respond to emergency conditions, take women’s blood 
pressures, assess proteinuria (using dipsticks at the first 
and any subsequently hypertensive visits) and use pulse 
oximetry (in Pakistan and Mozambique). For hyperten-
sive women, the POM application directed CHWs to 
administer oral methyldopa, intramuscular magnesium 
sulfate, or refer to a comprehensive emergency obstetric 
care facility depending on the particular circumstance. In 
the control group, women received routine antenatal and 
postnatal care. In all sites, postnatal care (as a standard) 
is rare, but antenatal care rates are high (76% receive at 
least four visits in Karnataka, 54% in Sindh and 51% in 
Mozambique). Antenatal care in all three sites typically 
takes place at local health or primary health centres on 
‘antenatal care days’ and is provided by a mix of care 
Key questions
What is already known?
 ► Recent reviews have indicated that many community health 
worker- led initiatives are cost- effective for maternal, neonatal and 
child health outcomes in low and middle- income countries (LMICs).
 ► Health economic analyses relating to interventions for the hyperten-
sive disorders of pregnancy have been based primarily on diagnos-
tic and clinical interventions.
What are the new findings?
 ► The Community- Level Interventions for Pre- eclampsia (CLIP) trials 
are the first to undertake a solely community- level intervention for 
pregnancy hypertension.
 ► Consistent with the primary trial data which demonstrated no 
overall benefit, the CLIP intervention was not cost- effective as 
implemented.
 ► When women received at least eight home- based visits from com-
munity health workers, there was a cost- effective reduction in a 
composite of maternal and perinatal mortality and morbidity, driven 
primarily by perinatal mortality.
 ► Data were broadly consistent across three diverse LMIC settings (in 
India, Pakistan and Mozambique), and provide support for the cost- 
effectiveness of community health worker- led interventions when 
staffing levels can support sufficient coverage of the population and 
frequency of contacts.
What do the new findings imply?
 ► The CLIP trials were not a cost- effective approach to reducing ad-
verse maternal and perinatal outcomes as implemented, but our 
findings of increasing cost- effectiveness with higher frequency of 
antenatal contacts support community- level intervention if scalabil-
ity can be achieved.
 ► Our data support a role for community health workers in delivering 
the eight antenatal care contacts model advocated by the WHO.
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providers. In both control and intervention arms, rele-
vant demographic, care- seeking and clinical data were 
obtained at enrolment, through to 28 days post partum 
(newborn) and 6 weeks (mother), through regular cross- 
sectional household surveys (every 3–6 months) and, in 
India, with additional facility record review.
Health systems
Each of the three healthcare systems has primary health 
centres, local inpatient facilities (combined with primary 
health centres in India), referral facilities and major 
referral centres. Each of the CLIP sites (Karnataka state 
in India, Sindh province in Pakistan, and Maputo and 
Gaza provinces in Mozambique) was a mix of rural and 
periurban settings and therefore does not represent the 
countries as a whole. In each setting, the CHWs have not 
been well integrated into any of the three formal health 
systems. The CLIP intervention was not a formal health 
system intervention.
Costs
Within each country, detailed costs associated with 
the intervention were collected from annual budgets, 
receipts and the number of intervention- related activi-
ties performed. Costs were divided into five main cate-
gories: (1) CHW training, (2) health worker incentives 
for providing POM visits, (3) drug administration costs 
resulting from POM visits, (4) community engage-
ment sessions (not including CHW staff costs), and (5) 
supplies; for details, see online supplemental table S2. 
Total cost of the intervention is the sum of these five cate-
gories. Discounting of costs was unnecessary due to the 
relatively short time period of the analysis (of less than 
2 years). In the main analyses, we did not account for 
potential costs associated with differences in care seeking 
(antenatally or postnatally) between intervention and 
control, as these measures were broadly similar between 
arms.7 9 10 In Pakistan, we included out- of- pocket costs to 
women, gathered by pilot- tested focus group discussions, 
in a separate analysis (online supplemental table S2). In 
India and Mozambique, trial resources and logistics did 
not permit these group discussions, and only the above 
incremental intervention costs were available. We did 
not have data available for control arm costs (beyond 
those above for Pakistan) and, therefore, these were not 
included in the analyses. We did not account for the cost 
of trial surveillance in both arms, as a potential scale- up 
of this intervention would not incur these costs. Costs 
for each country were converted into US$ rates based 
on the average exchange rate during the trial (ie, India: 
US$1=INR60, Pakistan: US$1=PKR104.7, Mozambique: 
US$1=MZN64.67).
Outcomes
The primary clinical endpoint was mortality for mothers 
and infants, including stillbirth and neonatal death. These 
rates were translated into years of life lost (YLL) based on 
country- specific WHO life expectancies.17 In contrast to 
the CLIP primary composite outcome, pregnancy- related 
morbidities for mothers and newborns were not included, 
as there are no validated years of life disabled or disabil-
ities associated with many of these outcomes in any of 
the three countries.18 Cost- effectiveness was summarised 
by incremental cost- effectiveness ratios (ICERs), which 
are interpreted as the average incremental cost relative 
to 1 year of life saved. That is, the cost that a policymaker 
would have to pay to extend life by 1 year.
Study perspective
The cost- effectiveness analyses were based on a program-
matic perspective, comparing the incremental cost of 
implementing the intervention both for the overall inter-
vention as delivered, and for various scenarios of POM- 
guided contacts delivered. This comparison assessed the 
cost to the health system of implementing the CLIP inter-
vention at various levels but did not account for potential 
additional costs to women and their families (ie, patient 
costs were not included), other than in a secondary anal-
ysis in Pakistan.
Data analyses
The primary economic model used for the base case anal-
ysis and probabilistic sensitivity analysis was a decision 
tree19 based on the following possible decision points: (1) 
arm of the trial; (2) number of POM contacts grouped 
into one of 0, 1–3, 4–7, or ≥8 (within intervention arm 
branch); (3) whether or not a POM- guided contact 
resulted in a referral to facility or use of either methyldopa 
or magnesium sulfate at any POM visit; and (4) outcome 
of pregnancy: maternal death, stillbirth, neonatal death 
or survival. See online supplemental figure S1 for details.
Within each country, the conditional probability at 
each branch was estimated directly from the CLIP trial 
surveillance and POM data. SEs for these probabilities 
were estimated and adjusted for the clustered structure 
of the data, and associated mean costs were estimated 
for each branch. Community engagement costs were 
assumed to be distributed evenly across the varying POM 
contact frequency groups. All other costs (CHW training 
and incentives, supplies, drugs) were distributed on a 
per contact basis, meaning branches on the tree corre-
sponded to groups with more POM- guided contacts and 
associated costs, to appropriately estimate the associated 
implementation cost of each frequency (‘scenario’) 
of the intervention. In addition, we also computed the 
average cost per visit by summing the non- community 
engagement- related costs (CHW training, CHW incen-
tives, drug administration and supplies) and dividing by 
the total number of visits.
We conducted a standard probabilistic sensitivity anal-
ysis20 to determine the uncertainty associated with our 
analyses. All analyses were carried out using R V.3.5.3 
and RStudio interface. For this, probability and costs 
for each branch were simulated using the above param-
eters. Costs were assumed to have gamma distributions, 
outcomes were assumed to have beta distributions and 
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the probability of each number of POM visits was drawn 
from a Dirichlet distribution (online supplemental table 
S3). These simulations were run 10 000 times for each 
country and the results summarised with 95% credible 
intervals (as the 2.5th and 97.5th percentiles of the 10 
000 runs) for the YLL, cost and ICERs for each trial arm 
as well as at each intervention scenario. Results were also 
visualised using a cost- effectiveness plane (with points 
in the top, right corner considered to be cost- effective), 
and with willingness- to- pay curves and thresholds for 
each YLL averted (which shows for increasing cost to a 
decision- maker the likelihood of the intervention is cost- 
effective). Willingness- to- pay thresholds based on (1) 
one and three times the country- specific gross domestic 
product (GDP) per capita in 2016 (India=$1729 and 
$5188, Mozambique=$429 and $1287, Pakistan=$1368 
and $4105) were used21 22 and (2) low and high- range 
estimates for country- level cost- effectiveness recently 
advocated (India=$115 and $770, Mozambique=$8 and 
$294, Pakistan=$87 and $669).23
Patient and public involvement
The design of the CLIP trials was informed by extensive 
in- country qualitative work with communities, including 
focus groups with women, men and other decision- 
makers, and community leaders.24–26 There was an expe-
rienced patient representative on the Technical Advisory 
Group responsible for ongoing study surveillance (see 
the Acknowledgements section). Dissemination activi-
ties have been held with the participating communities 
in each country, and feedback about the intervention 
from women was very positive (eg, ‘you have brought the 
hospital to my home’).
RESULTS
Data from 61 988 pregnancies of 69 320 enrolled in CLIP 
(89.4%) were included in the CLIP economic analyses: 
13 017 (88.1%) from India, 35 791 (90.8%) from Paki-
stan and 13 810 (91.3%) from Mozambique. The rates 
of maternal mortality, stillbirth and neonatal death did 
not differ between trial arms in any of the CLIP trials, 
but women receiving at least eight POM- guided contacts 
in India and Mozambique, and at least four contacts in 
Pakistan, had lower rates of each of these outcomes, with 
stillbirth (India and Pakistan) and neonatal mortality 
(Pakistan) being statistically significant, as previously 
reported.7–10 Outcome rates and trial intervention details 
can be found in table 1.
Given the varying trial sizes, total implementation costs 
varied between countries; however, estimates of intervention 
costs per pregnancy were similar: US$13.0 in India, US$11.8 
in Pakistan and US$15.7 in Mozambique. Table 2 shows that 
the majority of the costs in each country were related to POM- 
guided contacts and, therefore, costs were proportionately 
higher for women as they received an increasing number of 
contacts; the largest costs were for tablets and smartphones, 
and for the training of CHWs to deliver the intervention. In 
addition, costs in Pakistan were related to a much higher 
number of community engagement sessions compared with 
India and Mozambique. Other costs (eg, supplies) were 
similar on a per- pregnancy basis. Costs per POM visit were 
US$1.44, US$3.81 and US$2.65 in India, Mozambique and 
Pakistan, respectively. A complete detailed breakdown of 
costs can be found in online supplemental table S1.
In the base case analyses, the intervention was not 
found to be cost- effective in any of the three countries 
due to the lack of overall difference in maternal and 
perinatal mortality between arms (table 3). Similarly, 
in the probabilistic analyses, fewer than 50% of samples 
were cost- effective in Mozambique and India, and 66% 
were cost- effective in Pakistan (online supplemental 
table S4). However, when disaggregating the interven-
tion based on POM- guided contact frequency group, 
the groups receiving ≥8 contacts (per protocol) showed 
cost- effectiveness in the base case in each country 
(ICERs=43.3, 48.7 and 9.1 for each of India, Mozambique 
and Pakistan, respectively); in addition, the four to seven 
contact group was cost- effective in Pakistan (ICER=17.8). 
The cost- effectiveness plane (figure 1) depicts the results 
from the probabilistic sensitivity analyses; in each country, 
>80% of the probabilistic samples were found to be cost- 
effective for the ≥8 contact frequency group.
The cost- effectiveness acceptability curves (figure 2) 
show the probability of the intervention (for various 
scenarios) being cost- effective as a function of a decision- 
maker’s willingness to pay to save 1 YLL (log scale). In 
each country, if a decision- maker was willing to pay three 
times the GDP per capita (red dashed line), the ≥8 contact 
scenario (black solid line) has at least 90% certainty of 
cost- effectiveness. In Pakistan, at US$400/YLL, the prob-
ability of cost- effectiveness approaches near certainty 
(100%) for both the ≥8 and 4–7 contact scenarios (red 
dashed line). Similar findings in each country were 
found when the willingness- to- pay threshold was reduced 
to one times the GDP per capita and when willingness- 
to- pay thresholds were lowered to previously published 
country- specific recommendations.
In Pakistan, the secondary analyses focusing on a soci-
etal perspective (including out- of- pocket costs to women 
and their families) yielded similar results to the primary 
analysis, although with slightly higher costs associated 
with each intervention contact frequency group, corre-
sponding to slight increases in healthcare utilisation in 
the intervention arms. Details are in table 3.
DISCUSSION
Principal findings
This study assessed the cost- effectiveness for YLL, from 
the health system perspective, of the CLIP interventions 
in India, Pakistan and Mozambique. Using the Medical 
Research Council Process Evaluation of Complex Inter-
ventions guidance27 we observed that the incomplete 
implementation process overall resulted in no significant 
statistical difference in outcomes between trial arms, and, 
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therefore, a lack of cost- effectiveness. This was despite 
contextual adaptations of the generic protocol to create 
bespoke interventions for each country. However, once 
fidelity with the published protocol and implementation 
plan were achieved in terms of both dose and reach, 
maternal and perinatal mortality was significantly lower in 
women who received at least eight POM- guided contacts 
(four in Pakistan), and that in those scenarios the inter-
vention had a high probability of cost- effectiveness in 
each country. The cost of the intervention was remarkably 
similar between the three countries on a per- pregnancy 
basis (≈US$12–16). In addition, in Pakistan, although 
incremental costs were roughly twice as large, there were 
similar findings of cost- effectiveness when including 
women’s families’ opportunity (out- of- pocket) costs for 
health system resource utilisation.
Interpretation
Several recent reviews have summarised the current 
evidence on CHW- led initiatives,28–30 and many previous 


















1252 (18.1) 1157 (18.9) 1246 (18) 1172 (18.8) 5373 (29.1) 4187 (24.1)
Maternal mortality 
(%)
7 (0.1) 9 (0.1) 15 (0.2) 7 (0.1) 55 (0.3) 51 (0.3)
Maternal morbidity 
(%)
371 (5.4) 325 (5.3) 735 (10.6) 690 (11.1) 2213 (12) 1728 (10.0)
Stillbirth (%) 191 (2.8) 156 (2.6) 196 (2.8) 162 (2.6) 935 (5.1) 951 (5.5)
Neonatal death (%) 179 (2.6%) 136 (2.2) 218 (3.1) 171 (2.7) 1011 (5.5) 962 (5.5)
Neonatal morbidity 
(%)
813 (11.8) 790 (12.9) 275 (4.0) 362 (5.8) 2375 (12.9) 1684 (9.7)




1379 groups – 4243 groups 1379 groups 1368 groups
16 691 CHW led
–
CHWs trained 148 – 79 – 223 –
POM- guided 
contacts (n)




8.0 (3.0, 12.0) – 4.0 (2.0, 6.0) – 3.0 (2.0, 5.0) –
  0 770
(11.1%)
– 2796 (40.3%) – 7905
(42.9%)
–
  1–3 1268 (18.3%) – 936
(13.5%)
– 2718 (14.7%) –
  4–7 1363 (19.7%) – 1818 (26.2%) – 6008 (32.5%) –
  ≥8 3507 (50.8%) – 1391 (20.0%) – 1810 (9.8%) –
Pregnancies given 
methyldopa (%)
60 (1.0) – 28 (0.7) – 93 (0.9) –
  Accepted (%) 51 (85.0) – 19 (67.9) – 92 (98.9) –
Pregnancies given 
MgSO4 (%)
67 (1.1) – 28 (0.7) – 103 (1.0) –
  Accepted (%) 47 (70.5) – 13 (46.4) – 73 (70.9) –
Pregnancies 
referred to facility 
(%)
505 (8.2) – 263 (6.3) – 487 (4.6) –
  Accepted (%) 401 (86.7) – 158 (68.4) – 305 (83.6) –
CHW, community healthcare worker; MgSO4, magnesium sulfate; POM, PIERS (Pre- eclampsia Integrated Estimate of RiSk) On the 
Move.
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studies have identified cost- effectiveness for a variety 
of CHW- led interventions in reproductive, maternal, 
neonatal and child health,28 29 with further evidence 
supporting the use of integrated ‘packages’ of inter-
ventions.31 Despite this substantial body of informa-
tion, many maternal health studies still do not include 
a health economic component,14 and those focused on 
pre- eclampsia are based on diagnostic and clinical inter-
ventions, such as the use of magnesium sulfate.32 33 To 
our knowledge, this health economic analysis is the first 
to evaluate community- level interventions for pregnancy 
hypertension.
The observed differences in clinical and cost conse-
quence outcomes are unlikely to be due to behaviour 
change as the individual trial analyses did not identify 
increases in care seeking in the intervention (vs control) 
clusters.7–10 Therefore, our results are broadly consistent 
with prior findings, although requiring a frequency of 
contacts from CHWs that matches current WHO guid-
ance. Indeed, the consistently observed decrease in 
maternal and perinatal mortality, and increase in cost- 
effectiveness, with at least eight POM- guided contacts 
provides external validation of the recent WHO recom-
mendations for at least eight antenatal care contacts.34 
The contextual moderators that influenced the fidelity 
of implementation probably included the numbers of 
deployed CHWs, competing demands on CHW time 
(eg, ‘immunisation months’), the variable resilience of 
the emergency transport system once women at risk were 
identified and the timeliness and quality of the clinical 
responses as women ascended the referral system.
Although the overall per- pregnancy costs were similar 
between countries, there was discrepancy in the cost of 
delivering at least eight POM- guided contacts, which 
was largely driven by differences in CHW training and 
incentive costs per pregnancy. When considering at- s-
cale implementation of interventions such as CLIP 
that require a high number of contacts to be effective, 
these cost differences would be important to consider, 
as CHW salaries and relative affordability differ between 
LMICs.35 36 That said, the relatively low cost in each 
country supports CHWs carrying out home- based visits 
during pregnancy in LMICs where interventions are 
urgently needed to reduce the burden of maternal and 
perinatal mortality.
The out- of- pocket costs to women in Pakistan were 
much higher than those based on the incremental cost 
of the intervention to the health system, and reveal the 
significant burden placed on families in order to seek 
appropriate routine and emergency care, obtain trans-
port to facility and be admitted to health facilities for 
delivery. These costs reflect productivity losses due to 
pregnancy and pregnancy complications. As most fami-
lies do not have sufficient savings, without societal safety 
nets, large pregnancy- related expenditures are a barrier 
for upward social mobility.37 Given the underlying differ-
ences in healthcare systems, the generalisation of these 
secondary societal results to India, Mozambique or other 
LMIC settings should be interpreted cautiously.
Strengths
Our study has several strengths. First, we prospectively 
collected both cost and outcome data within our clinical 
trial.11 Second, we implemented our intervention across 
three diverse settings in Africa and South Asia, and with 
a large sample size of >60 000 pregnant women overall. 
Therefore, we believe that our findings are generalisable 
to other LMIC settings. Further, the details of our budget 
allow for clear understanding of the cost of scaling any 
one or all components of the intervention. In the case of 
Table 2 Summary costs for intervention by country
India Mozambique Pakistan
Training of CHWs 12 755 53 205 79 398*
Incentives for delivering POM contacts 39 043 3097
Methyldopa and MgSO4 1365 7163 4864
Community engagement 7048 9201 71 942
Supplies 29 811 45 383 60 949
Total 90 022 108 848 217 153
Total per pregnancy overall 13.0 15.7 11.8
  0 POM- guided contact 1.01 1.35 3.91
  1–3 POM- guided contacts 3.51 9.66 9.56
  4–7 POM- guided contacts 8.06 22.10 17.48
  ≥8 POM- guided contacts 18.61 39.45 25.78
Cost of each POM visit† 1.44 3.81 2.65
All costs in US$.
*Unable to be disaggregated from available data.
†Sum of non- community engagements divided by total number of visits.
CHW, community healthcare worker; POM, PIERS (Pre- eclampsia Integrated Estimate of RiSk) On the Move.
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Pakistan, we found similar cost- effectiveness at increased 
POM contacts (but not for the overall intervention) 
when including data on out- of- pocket costs to women 
and their families, and, therefore, providing a broader 
societal perspective on the cost- effectiveness.
We were further able to corroborate our main findings 
by including data on out- of- pocket costs to women and 
their families, and, therefore, providing a broader soci-
etal perspective on the cost- effectiveness.
Limitations
The main challenge associated with our economic anal-
yses is that we were unable to use disability- adjusted 
life- years (DALY) that include maternal and perinatal 
morbidity as an outcome measure. This is due to a lack 
of reliable DALYs for the collected morbidities in each of 
India, Pakistan and Mozambique. Given that we consist-
ently observed similar results in maternal morbidity (no 
effect overall, decrease with at least eight POM contacts) 
to mortality8 it is probable that the cost- effectiveness 
results seen here would be similar if this could be 
included.
On the other hand, survived neonatal morbidity was 
in some cases increased in the ≥8 POM contact group, 
suggesting a trade- off between reduced mortality in this 
group and increased survivable morbidity in neonates, 
which would require further exploration to determine 
severity as well as the values of women, healthcare 
providers and their communities. Therefore, the inclu-
sion of these data may have reduced the estimates of cost- 
effectiveness seen here.
Furthermore, given the scale of the trial and complex-
ities of the health systems, reliable data on the out- of- 
pocket costs to women and health system costs associated 
with being referred were unavailable in India and Mozam-
bique; this limits our conclusions to that of a health system 
perspective, rather than the preferred ‘societal’ approach 
in these two countries.38 Further, the lack of feasibility for 
collecting of out- of- pocket costs prevented us from doing 
Figure 1 Probabilistic sensitivity analyses of cost- effectiveness by number of POM- guided contacts received. Points in the 
north- east quadrant are classified as cost- effective. All data are per 1000 pregnancies. ctrl, control; int, intervention; POM, 
PIERS (Pre- eclampsia Integrated Estimate of RiSk) On the Move.
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an individual patient- level cost- effectiveness analysis. In 
Pakistan, estimates of family opportunity cost data were 
available from focus groups, and cost- effectiveness results 
were broadly similar to the programmatic perspective. 
These analyses relied on extrapolating these estimates to 
the larger trial population and therefore should be inter-
preted cautiously.
In addition, we did not adjust costs for differences in 
routine antenatal care seeking between arms as these 
measures and the associated cost were not available. 
Despite this, these measures were broadly similar between 
trial arms, and, therefore, we do not anticipate that this 
influenced the results.7 9 10 The CLIP trials relied on 
leveraging existing CHWs in each of the sites, and there-
fore we did not measure costs associated with increasing 
the number of CHWs, only the training and materials 
associated with the CLIP intervention. Therefore, there 
would therefore be higher costs in settings where CHWs 
are understaffed or not employed.
Finally, the decision tree model used could not adjust 
for differences between women who received a low and 
high number of POM visits that would have an impact 
on mortality, which may introduce a bias due to possible 
confounding. That being said, in the analyses of the 
primary trial data, adjustment for such measured differ-
ences did not affect the association between increased 
visits and reduced outcomes.7–10
Meaning
Depending on a decision- maker’s willingness to pay, 
having CHWs deliver home- based interventions at WHO- 
recommended frequency thresholds is probably a cost- 
effective method for reducing maternal and perinatal 
mortality. Reaching these contact frequencies for all 
women may be challenging without resources beyond 
Figure 2 Cost- effectiveness acceptability curves by number of POM- guided contacts received: probability that the 
intervention is cost- effective as a function of a decision- maker’s willingness to pay to save 1 year of life lost. The vertical red 
line represents country- specific willingness- to- pay thresholds based on 1× and 3× the gross domestic product (GDP) per 
capita. The vertical blue lines represent the low and high points of country- specific willingness- to- pay ranges from Woods et 
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those available in CLIP. The similarity in the cost of CHW 
visits and per- pregnancy trial costs overall between coun-
tries points to generalisability to other LMICs.
Future work
As further emphasis is placed on increasing the number 
of antenatal contacts in LMICs, future studies should 
continue to assess the cost- effectiveness of delivering 
these contacts, and integrated interventions by CHWs. 
Our data suggest that CHW- based interventions can 
be effective and cost- effective if a sufficient number of 
workers are available to deliver them at the required 
frequency. Future studies should estimate both health 
system and societal perspective costs in settings where 
families bare the cost of facility- based care. In addition, 
there is a need for continued development of ‘years- of- 
life- disabled’ metrics for pregnancy- specific morbidities 
so that trials can better estimate the economic impact of 
their interventions.
CONCLUSION
While the CLIP intervention as implemented was not 
cost- effective at reducing YLL in any of the three coun-
tries, when implemented with at least eight POM- guided 
contacts per pregnancy, there was both a reduction in 
YLL and a high probability of cost- effectiveness in each 
of the three CLIP countries. This supports the eight ante-
natal care contacts model advocated by the WHO.
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